Compare Kyndryl Holdings Inc (KD) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Revvity Inc — how do they compare? Kyndryl Holdings Inc trades at $11.69 (market cap $2.59B), while Revvity Inc trades at $154.88 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 6.6× Kyndryl Holdings Inc's market cap, and Revvity Inc pays a 0.18% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kyndryl Holdings Inc for 36 Days and Revvity Inc for 12 Days on average.
| KD | RVTY | |
|---|---|---|
Market Cap | $2.59B | $16.98B |
Volume | 5,354,348 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $29.76 | $157.36 |
52-Week Low | $10.59 | $82.26 |
Typical Hold Time | 36 Days | 12 Days |
Enterprise Value | $5.41B | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl (KD) trades at $11.67, up 1.92% today, with a bearish technical signal and neutral oscillators. The company reported a return to profitability in 2025 with net income of $252 million, though revenue has declined from $18.3B in 2022 to $15.1B. Recent news highlights a strategic focus on AI, including a new innovation lab and acquisitions, aiming to drive future growth amid competitive pressures.
The outlook is mixed: positive cash flow and low EV/EBITDA suggest value, but declining revenue and modest analyst consensus ($14.67 target) indicate caution. Key risks include execution on AI initiatives and sustained top-line pressure. Institutional sentiment is neutral with 71% hold ratings, reflecting a wait-and-see approach amid transformation efforts.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
